CY1123033T1 - Σπειροκυκλικοι αναστολεις της καθεψινης c - Google Patents
Σπειροκυκλικοι αναστολεις της καθεψινης cInfo
- Publication number
- CY1123033T1 CY1123033T1 CY20191101154T CY191101154T CY1123033T1 CY 1123033 T1 CY1123033 T1 CY 1123033T1 CY 20191101154 T CY20191101154 T CY 20191101154T CY 191101154 T CY191101154 T CY 191101154T CY 1123033 T1 CY1123033 T1 CY 1123033T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cathepsin
- spirocyclic
- inhibitors
- dipeptidyl
- peptidase
- Prior art date
Links
- 102000005600 Cathepsins Human genes 0.000 title 1
- 108010084457 Cathepsins Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000003902 Cathepsin C Human genes 0.000 abstract 1
- 108090000267 Cathepsin C Proteins 0.000 abstract 1
- 229940122524 Cathepsin C inhibitor Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14184613 | 2014-09-12 | ||
| PCT/EP2015/070449 WO2016038007A1 (en) | 2014-09-12 | 2015-09-08 | Spirocyclic inhibitors of cathepsin c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123033T1 true CY1123033T1 (el) | 2021-10-29 |
Family
ID=51535355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101154T CY1123033T1 (el) | 2014-09-12 | 2019-11-06 | Σπειροκυκλικοι αναστολεις της καθεψινης c |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US9540373B2 (https=) |
| EP (2) | EP3511331A1 (https=) |
| JP (2) | JP2017526716A (https=) |
| KR (1) | KR102510588B1 (https=) |
| CN (2) | CN107074870B (https=) |
| AP (1) | AP2017009733A0 (https=) |
| AU (1) | AU2015314355B2 (https=) |
| BR (1) | BR112017003433B1 (https=) |
| CA (1) | CA2960916C (https=) |
| CL (1) | CL2017000432A1 (https=) |
| CO (1) | CO2017002268A2 (https=) |
| CY (1) | CY1123033T1 (https=) |
| DK (1) | DK3191487T3 (https=) |
| EA (1) | EA031376B1 (https=) |
| ES (1) | ES2749009T3 (https=) |
| HK (1) | HK1255362A1 (https=) |
| HR (1) | HRP20191756T1 (https=) |
| HU (1) | HUE047208T2 (https=) |
| IL (1) | IL250262B (https=) |
| LT (1) | LT3191487T (https=) |
| MX (2) | MX367316B (https=) |
| MY (1) | MY188382A (https=) |
| NZ (1) | NZ728684A (https=) |
| PE (1) | PE20170438A1 (https=) |
| PH (1) | PH12017500453B1 (https=) |
| PL (1) | PL3191487T3 (https=) |
| PT (1) | PT3191487T (https=) |
| RS (1) | RS59444B1 (https=) |
| SA (1) | SA517381064B1 (https=) |
| SG (1) | SG11201701633SA (https=) |
| SI (1) | SI3191487T1 (https=) |
| TW (1) | TWI687424B (https=) |
| UA (1) | UA118610C2 (https=) |
| WO (1) | WO2016038007A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9018227B2 (en) | 2010-03-19 | 2015-04-28 | Indiana State University | Nicotinic acetylcholine receptor agonists |
| NO2699580T3 (https=) | 2014-01-24 | 2018-02-24 | ||
| JP6529575B2 (ja) * | 2014-08-01 | 2019-06-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用 |
| EP3511331A1 (en) | 2014-09-12 | 2019-07-17 | Boehringer Ingelheim International GmbH | Spirocyclic inhibitors of cathepsin c |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2018162312A1 (en) * | 2017-03-10 | 2018-09-13 | Basf Se | Spirocyclic derivatives |
| CA3089240A1 (en) * | 2018-02-07 | 2019-08-15 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides |
| HUE070049T2 (hu) | 2018-03-01 | 2025-05-28 | Astrazeneca Ab | (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil} -1,4-oxazepán-2-karboxamidot tartalmazó gyógyászati készítmények |
| WO2020018547A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| CN110256429B (zh) * | 2019-06-17 | 2021-06-22 | 广东药科大学 | 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用 |
| CN110257504A (zh) * | 2019-06-30 | 2019-09-20 | 中南大学 | 一种难治性哮喘检测标记物的筛选方法及其应用 |
| EP4182700A4 (en) | 2020-07-20 | 2024-11-13 | Insmed Incorporated | METHODS FOR EXTRACTING NEUTROPHIL SERINE PROTEASES AND TREATMENT OF DIPETIDYL PEPTIDASE-1-MEDIATED DISEASES |
| CN114106005B (zh) * | 2020-08-26 | 2025-08-01 | 西藏海思科制药有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| AU2021381509A1 (en) * | 2020-11-17 | 2023-06-22 | Vertex Pharmaceuticals Incorporated | Solid forms of 4-(5-(4-fluorophenyl)-6-tetrahydro-2h-pyran-4-yl)- 1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid |
| KR20230117738A (ko) * | 2020-12-04 | 2023-08-09 | 레이스톤 바이오파마 컴퍼니 리미티드 | 카텝신 c의 소분자 억제제 및 이의 의약적 용도 |
| CN114591315A (zh) * | 2020-12-04 | 2022-06-07 | 瑞石生物医药有限公司 | 一种组织蛋白酶c小分子抑制剂 |
| AU2023296161A1 (en) * | 2022-06-13 | 2025-01-02 | Alivexis, Inc. | Azacycloalkyl carbonyl cyclic amine compound |
| EP4551554A1 (en) | 2022-07-06 | 2025-05-14 | Chiesi Farmaceutici S.p.A. | Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors |
| WO2024088307A1 (zh) * | 2022-10-26 | 2024-05-02 | 上海壹迪生物技术有限公司 | 一种新型肽基腈类化合物及其应用 |
| JP2026503035A (ja) | 2023-01-06 | 2026-01-27 | インスメッド インコーポレイテッド | 新規な可逆性ｄｐｐ１阻害剤及びその用途 |
| WO2025214464A1 (en) * | 2024-04-12 | 2025-10-16 | Insmed Incorporated | Crystalline forms of (s) -n- (1-cyano-2- (2-fluoro-4- (1' - (oxetan-3-yl) -3h-spiro [isobenzofuran-1, 4' -piperidin] -6-yl) phenyl) ethyl) -2-azabicyclo [2.2.2] octane-1-carboxamide |
| WO2026046911A1 (en) | 2024-08-27 | 2026-03-05 | Boehringer Ingelheim International Gmbh | A dipeptidyl-peptidase i inhibitor for its use in the treatment of anca-associated vasculitis |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4125727A (en) | 1976-10-18 | 1978-11-14 | American Cyanamid Company | Method of preparing imidazoisoindolediones |
| GB8922355D0 (en) | 1989-10-04 | 1989-11-22 | British Telecomm | Sealing gland |
| GEP20012487B (en) | 1998-09-16 | 2001-07-25 | Merab Lomia | Use of Chemical Agent 5-carbarnoyl-5H-Dibenz (b,f) azepin, its Derivatives and Analogues by New Purpose |
| US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| CA2439415C (en) | 2001-03-02 | 2011-09-20 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| TW200306189A (en) | 2002-03-21 | 2003-11-16 | Merz Pharma Gmbh & Co Kgaa | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| JP2006527704A (ja) | 2003-06-18 | 2006-12-07 | プロザイメックス・アクティーゼルスカブ | プロテアーゼ阻害剤 |
| TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
| WO2006096807A1 (en) | 2005-03-08 | 2006-09-14 | Janssen Pharmaceutica N.V. | Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists |
| UA100669C2 (ru) * | 2006-06-01 | 2013-01-25 | Санофі-Авентіс | Спироциклические нитрилы как ингибиторы протеазы, способ их получения (варианты) и лекарственное средство на их основе |
| US20090247560A1 (en) | 2006-09-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| WO2009047829A1 (ja) | 2007-10-12 | 2009-04-16 | Fujitsu Limited | Ｉｐ電話自動試験システム及び方法 |
| US7902181B2 (en) | 2007-12-12 | 2011-03-08 | Astrazeneca Ab | Compounds 010 |
| MX2011011661A (es) | 2009-05-07 | 2011-11-18 | Astrazeneca Ab | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750. |
| WO2010142985A1 (en) | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
| WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
| US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| AU2013254657B2 (en) | 2012-04-27 | 2015-12-24 | Glaxo Group Limited | Novel compounds |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| SG11201408284VA (en) | 2012-05-22 | 2015-02-27 | Xenon Pharmaceuticals Inc | N-substituted benzamides and their use in the treatment of pain |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| KR102215272B1 (ko) | 2012-09-28 | 2021-02-15 | 이그니타, 인코포레이티드 | 비정형 단백질 키나제 c의 아자퀴나졸린 억제제 |
| JP2015533134A (ja) * | 2012-10-09 | 2015-11-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 錠剤の機械的安定性に適切な少なくとも１種の水和物形成活性物質及び／又はアジュバントを含有する機械的に安定な錠剤、特にアルギニン含有錠剤の製造における選択的に水分調整された打錠材料の使用 |
| PE20150887A1 (es) | 2012-10-15 | 2015-06-04 | Epizyme Inc | Compuestos de benceno sustituidos |
| US9290476B2 (en) | 2012-10-16 | 2016-03-22 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
| TWI646099B (zh) | 2012-11-01 | 2019-01-01 | 英塞特控股公司 | 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物 |
| MX365640B (es) | 2012-12-21 | 2019-06-10 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas y sus indicaciones. |
| BR112015014968A2 (pt) | 2012-12-21 | 2017-07-11 | Quanticel Pharmaceuticals Inc | inibidores de histona-desmetilase |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| MX2015009952A (es) | 2013-02-08 | 2015-10-05 | Celgene Avilomics Res Inc | Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos. |
| AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| KR20150126623A (ko) | 2013-03-14 | 2015-11-12 | 뉴링크 제네틱스 코퍼레이션 | 트립토판 대사로 인한 면역억제의 억제제로서의 삼환식 화합물 |
| JO3383B1 (ar) | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
| JP6387360B2 (ja) | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン |
| EP2970252B1 (en) * | 2013-03-14 | 2020-06-03 | Boehringer Ingelheim International GmbH | Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調節劑 |
| ES2845473T3 (es) * | 2013-03-14 | 2021-07-26 | Boehringer Ingelheim Int | (Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C |
| JP6330058B2 (ja) * | 2014-04-29 | 2018-05-23 | ケアベイ・ヨーロッパ・リミテッドＣａｒｅｂａｙ Ｅｕｒｏｐｅ Ｌｉｍｉｔｅｄ | 針の挿入深さを調節する装置 |
| EP3164272A1 (en) | 2014-07-03 | 2017-05-10 | Bridgestone Americas Tire Operations, LLC | Sidewall decoration on rim guard |
| TW201625591A (zh) | 2014-09-12 | 2016-07-16 | 美國禮來大藥廠 | 吖丁啶基氧苯基吡咯啶化合物 |
| EP3511331A1 (en) * | 2014-09-12 | 2019-07-17 | Boehringer Ingelheim International GmbH | Spirocyclic inhibitors of cathepsin c |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| BR112017004580A2 (pt) | 2014-09-12 | 2018-01-23 | GlaxoSmithKline Intellectual Property | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. |
-
2015
- 2015-09-08 EP EP19155235.5A patent/EP3511331A1/en not_active Withdrawn
- 2015-09-08 SI SI201530977T patent/SI3191487T1/sl unknown
- 2015-09-08 EA EA201790576A patent/EA031376B1/ru not_active IP Right Cessation
- 2015-09-08 WO PCT/EP2015/070449 patent/WO2016038007A1/en not_active Ceased
- 2015-09-08 CA CA2960916A patent/CA2960916C/en active Active
- 2015-09-08 KR KR1020177009993A patent/KR102510588B1/ko active Active
- 2015-09-08 MX MX2017003156A patent/MX367316B/es active IP Right Grant
- 2015-09-08 CN CN201580048467.6A patent/CN107074870B/zh active Active
- 2015-09-08 CN CN201810030066.3A patent/CN108047240B/zh active Active
- 2015-09-08 UA UAA201703350A patent/UA118610C2/uk unknown
- 2015-09-08 EP EP15757523.4A patent/EP3191487B1/en active Active
- 2015-09-08 LT LTEP15757523.4T patent/LT3191487T/lt unknown
- 2015-09-08 SG SG11201701633SA patent/SG11201701633SA/en unknown
- 2015-09-08 NZ NZ728684A patent/NZ728684A/en unknown
- 2015-09-08 AP AP2017009733A patent/AP2017009733A0/en unknown
- 2015-09-08 AU AU2015314355A patent/AU2015314355B2/en active Active
- 2015-09-08 RS RSP20191350 patent/RS59444B1/sr unknown
- 2015-09-08 PL PL15757523T patent/PL3191487T3/pl unknown
- 2015-09-08 BR BR112017003433-6A patent/BR112017003433B1/pt active IP Right Grant
- 2015-09-08 DK DK15757523T patent/DK3191487T3/da active
- 2015-09-08 PE PE2017000400A patent/PE20170438A1/es unknown
- 2015-09-08 PT PT157575234T patent/PT3191487T/pt unknown
- 2015-09-08 HR HRP20191756TT patent/HRP20191756T1/hr unknown
- 2015-09-08 ES ES15757523T patent/ES2749009T3/es active Active
- 2015-09-08 HU HUE15757523A patent/HUE047208T2/hu unknown
- 2015-09-08 JP JP2017513658A patent/JP2017526716A/ja not_active Ceased
- 2015-09-08 MY MYPI2017000213A patent/MY188382A/en unknown
- 2015-09-08 MX MX2019009695A patent/MX378099B/es unknown
- 2015-09-10 US US14/849,710 patent/US9540373B2/en not_active Ceased
- 2015-09-11 TW TW104130165A patent/TWI687424B/zh active
-
2016
- 2016-11-29 US US15/362,949 patent/US9879026B2/en active Active
-
2017
- 2017-01-24 IL IL250262A patent/IL250262B/en active IP Right Grant
- 2017-02-23 CL CL2017000432A patent/CL2017000432A1/es unknown
- 2017-03-07 CO CONC2017/0002268A patent/CO2017002268A2/es unknown
- 2017-03-09 SA SA517381064A patent/SA517381064B1/ar unknown
- 2017-03-10 PH PH12017500453A patent/PH12017500453B1/en unknown
- 2017-11-30 US US15/827,433 patent/USRE47636E1/en active Active
- 2017-12-22 JP JP2017246001A patent/JP6360961B2/ja active Active
-
2018
- 2018-11-14 HK HK18114501.3A patent/HK1255362A1/zh unknown
-
2019
- 2019-11-06 CY CY20191101154T patent/CY1123033T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123033T1 (el) | Σπειροκυκλικοι αναστολεις της καθεψινης c | |
| CY1125214T1 (el) | Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος | |
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| EA201691354A1 (ru) | Терапевтические ингибирующие соединения | |
| BR112017013440A2 (pt) | compostos de isoquinolina para o tratamento de hiv | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| EA201691857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| MX372997B (es) | Compuestos de aminopirimidina como inhibidores de jak. | |
| EA201790271A1 (ru) | Ингибиторы гликозидазы | |
| CY1120751T1 (el) | Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων | |
| MX380250B (es) | Compuestos farmacéuticos inhibidores de cinasa chk-1. | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| MX2019006893A (es) | Inhibidores heterociclicos de mct4. | |
| BR112016018062A8 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| CY1122313T1 (el) | Ορβεπιταντη για την αγωγη του χρονιου κνησμου | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
| EA201690783A1 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| EA201791174A1 (ru) | Антимикотическое соединение | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. |